Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARWR
stocks logo

ARWR

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-1.101
-20.19%
--
--
-0.419
-69.38%
--
--
-0.513
-63.07%
Estimates Revision
The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2025, with the revenue forecasts being adjusted by 98.19% over the past three months. During the same period, the stock price has changed by 13.95%.
Revenue Estimates for FY2025
Revise Upward
up Image
+98.19%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-94.1%
In Past 3 Month
Stock Price
Go Up
up Image
+13.95%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 41.44 USD with a low forecast of 17.00 USD and a high forecast of 80.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
4 Hold
0 Sell
Moderate Buy
up Image0
Current: 15.930
sliders
Low
17.00
Averages
41.44
High
80.00
up Image0
Current: 15.930
sliders
Low
17.00
Averages
41.44
High
80.00
UBS
Buy
to
Buy
downgrade
$71 -> $63
2025-05-14
Reason
UBS
Price Target
$71 -> $63
2025-05-14
downgrade
Buy
to
Buy
Reason
UBS lowered the firm's price target on Arrowhead to $63 from $71 and keeps a Buy rating on the shares.
Citi
Neutral
downgrade
$21 -> $17
2025-05-13
Reason
Citi
Price Target
$21 -> $17
2025-05-13
downgrade
Neutral
Reason
Citi lowered the firm's price target on Arrowhead to $17 from $21 and keeps a Neutral rating on the shares. The company reported fiscal Q2 financial results and gave progress updates on its "extensive" pipeline of over 15 assets in development, the analyst tells investors in a research note. The firm says that while the decision to pay down some of its credit facility will be seen positively by some investors, it still sees a "low ceiling for shares" in the short term due to limited upside for the familial chylomicronemia syndrome launch.
B. Riley Securities
Mayank Mamtani
Strong Buy
Reiterates
$51 → $38
2025-02-14
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$51 → $38
2025-02-14
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$80
2025-02-12
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$80
2025-02-12
Reiterates
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$60
2025-02-11
Reason
Chardan Capital
Keay Nakae
Price Target
$60
2025-02-11
Maintains
Strong Buy
Reason
RBC Capital
Luca Issi
Buy
Reiterates
$42
2025-02-11
Reason
RBC Capital
Luca Issi
Price Target
$42
2025-02-11
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR.O) is -4.91, compared to its 5-year average forward P/E of -29.31. For a more detailed relative valuation and DCF analysis to assess Arrowhead Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-29.31
Current PE
-4.91
Overvalued PE
4.34
Undervalued PE
-62.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-30.57
Current EV/EBITDA
-9.11
Overvalued EV/EBITDA
6.03
Undervalued EV/EBITDA
-67.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
26.11
Current PS
7.19
Overvalued PS
39.73
Undervalued PS
12.48

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

ARWR News & Events

Events Timeline

(ET)
2025-08-01
06:50:37
Arrowhead announces asset purchase agreement between Sanofi, Visirna
select
2025-07-28 (ET)
2025-07-28
12:02:53
Sarepta tells Bloomberg expects to honor Arrowhead commitments
select
2025-07-28
07:33:34
Arrowhead earns $100M milestone payment from Sarepta
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.5
08-01Newsfilter
PinnedArrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

  • Sanofi's Acquisition of Plozasiran: Sanofi has entered into an agreement to pay $130 million upfront and up to $265 million in potential milestones to Visirna Therapeutics for the rights to develop and commercialize investigational plozasiran in Greater China, targeting conditions related to elevated triglycerides.

  • Clinical Progress and Designations: Plozasiran has successfully completed a Phase 3 trial for familial chylomicronemia syndrome (FCS) in China, received Breakthrough Therapy Designation, and is currently under review by the National Medical Products Administration (NMPA) for marketing authorization.

Preview
8.5
08-01SeekingAlpha
Arrowhead unit sells rights for plozasiran to Sanofi in Greater China

  • Asset Purchase Agreement: Arrowhead Pharmaceuticals has signed an agreement with Sanofi for the exclusive rights to develop and commercialize plozasiran, a treatment for high triglyceride levels, in Greater China through its subsidiary Visirna Therapeutics.

  • Financial Terms: Sanofi will pay Arrowhead an initial $130 million, with potential additional payments of up to $265 million based on regulatory milestones, while Arrowhead will also earn royalties from sales in the region.

Preview
9.0
07-29Benzinga
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?

  • FDA Decision on Elevidys: Sarepta Therapeutics' stock rose 41.05% after the FDA recommended lifting the voluntary hold on Elevidys, its gene therapy for Duchenne Muscular Dystrophy, following a review that deemed an 8-year-old patient's death unlikely related to the treatment.

  • Ongoing Challenges and Financial Obligations: Despite the positive FDA news, distribution for non-ambulatory patients remains on hold as discussions with the FDA continue, while Arrowhead Pharmaceuticals has claimed Sarepta owes them $100 million due within 60 days.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

The current price of ARWR is 15.93 USD — it has increased 0.82 % in the last trading day.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR)'s business?

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

arrow icon

What is the price predicton of ARWR Stock?

Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 41.44 USD with a low forecast of 17.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR)'s revenue for the last quarter?

Arrowhead Pharmaceuticals Inc revenue for the last quarter amounts to 542.71M USD, decreased % YoY.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR)'s earnings per share (EPS) for the last quarter?

Arrowhead Pharmaceuticals Inc. EPS for the last quarter amounts to 2.75 USD, decreased -369.61 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arrowhead Pharmaceuticals Inc (ARWR)'s fundamentals?

The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2025, with the revenue forecasts being adjusted by 98.19% over the past three months. During the same period, the stock price has changed by 13.95%.
arrow icon

How many employees does Arrowhead Pharmaceuticals Inc (ARWR). have?

Arrowhead Pharmaceuticals Inc (ARWR) has 609 emplpoyees as of August 03 2025.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR) market cap?

Today ARWR has the market capitalization of 2.20B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free